Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd.

August 14, 2007 13:03 ET

Urodynamix Warrant Exercise Raises $900,000

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 14, 2007) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced receipt of an additional $897,600 in gross proceeds from the exercise of share purchase warrants issued as part of a private placement in 2005.

A total of 94% of the outstanding warrants were exercised. As a result, Urodynamix currently has approximately $3.8 million of cash on hand to fund operations and working capital requirements.

"We are very pleased with the success of our warrant financing strategy, which has allowed us to successfully complete several important clinical studies and accelerate the development and commercialization of our URO-NIRS Bladder Monitor technology," said Barry Allen, President and CEO. "This funding represents yet another vote of confidence in our business model and provides further scope to support the development and launch of our innovative medical technology in the months ahead."

Urodynamix currently has outstanding 81,302,893 common shares and 6,909,000 incentive stock options.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for large and growing global healthcare markets. The Company is currently developing medical devices that use near-infrared spectroscopy (NIRS) to aid in the diagnosis and treatment of urological conditions, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. Urodynamix's disruptive technology has the potential to beneficially affect more than 200 million people worldwide.

On behalf of the Board,

Barry Allen, President & CEO

Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information